You are here

  • Home
  • Archive
  • Volume 25, Issue 4
  • High effectiveness of papillomavirus vaccination in preventing cervical cancer: is not it time for low-income and middle-income countries to reap the benefits?

Article Text

Article menu
Download PDFPDF
Commentary
Health promotion and public health
High effectiveness of papillomavirus vaccination in preventing cervical cancer: is not it time for low-income and middle-income countries to reap the benefits?
  1. Saivash Moradi
  1. Medical Education Development Centre, Mazandaran University of Medical Sciences Faculty of Medicine, Sari, Iran
  1. Correspondence to Professor Saivash Moradi, Mazandaran University of Medical Sciences Faculty of Medicine, Sari, Iran (the Islamic Republic of); d.smor86{at}yahoo.com

https://doi.org/10.1136/ebnurs-2022-103513

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Falcaro M, Castañon A, Ndlela B, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade three cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet 2021; Dec 4;398 (10316):2084–2092.

    Implications for practice and research

    • The high burden of cervical cancer in low-income and middle-income countries highlights the need for early prevention.

    • Research on the beneficial effects of papillomavirus vaccination in low-income and middle-income countries is a priority.

    Context

    International agency for research on cancer estimated that nearly 604 000 women were diagnosed with cervical cancer and about 342 000 women died from the disease worldwide in 2020.1 The main cause of cervical cancer is persistent infection with high-risk oncogenic strains of human papillomavirus (HPV) including 16 and 18. Vaccination against high-risk HPV types, …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.